Our funds
The fund

Fondita Healthcare is an actively managed, global healthcare fund. In line with the Article 9 sustainability rating, the fund’s social sustainability objective is to invest in companies that promote health and well-being, as well as access to healthcare and equality in their own business operations.

Healthcare

The fund invests in companies that address current and unmet medical needs and provide access to medicine and medical care. This is achieved by investing in companies active in innovation, production and distribution of medicines and healthcare equipment, tools and supplies as well as diagnostics and healthcare services. Operationally, the companies are to act in a socially and environmentally responsible way.

Healthcare is an incredibly interesting, structurally growing sector and one of the three megatrends that Fondita’s thematic funds invest in.

Demographic changes with an ageing population, as well as increased welfare, translate into growing demand for healthcare. Innovation and technological advances improve care and deliver new products to fulfil current and unmet demand fueling the sector’s growth.

Sustainability
Read more about the fund’s sustainability principles:

Portfolio managers

Marcus Björkstén

Portfolio Manager, Head of Portfolio Management
Fund facts

31.12.2025

Fund size (M€)
21,9
ISIN (A)
FI4000321088
ISIN (B)
FI4000321096
Currency
EUR
Management fee
2,00 % p.a.
Risk indicator
4/7
SFDR Classification
Article 9
The fund manager's comment
The final month of the year did not bring any major movements to the global equity markets. The most significant event was the anticipated interest rate cut by the Fed at the beginning of December. European equities outperformed broad global equity indices in December (in EUR). This trend also characterized the entire year of 2025. As usual, liquidity declined toward the e...
Top holdings
Eli Lilly (US)
9,3 %
AstraZeneca (SE)
5,3 %
Medtronic (US)
5,1 %
Merck & Co (US)
4,5 %
Stryker (US)
4,1 %
USA
48 %
Denmark
13 %
Sweden
11 %
Switzerland
9 %
Belgium
7 %
Return
1 month
-3,0 %
3 months
6,8 %
6 months
7,6 %
YTD
-4,3 %
1 year
-4,3 %
3 years
12,7 %
5 years
6,0 %
since launch (14.6.2018)
46,3 %
since launch p.a.
5,2 %
Sector division
Pharma
62 %
Equipment
36 %
Cash
2 %
Top 10 holdings
Eli Lilly (US)
9,3 %
AstraZeneca (SE)
5,3 %
Medtronic (US)
5,1 %
Merck & Co (US)
4,5 %
Stryker (US)
4,1 %
Boston Scientific (US)
4,1 %
Jazz Pharmaceuticals (US)
4,0 %
Novo Nordisk (DK)
3,8 %
ALK-Abelló (DK)
3,8 %
Onward Medical (BE)
3,5 %
Country division
USA
48 %
Denmark
13 %
Sweden
11 %
Switzerland
9 %
Belgium
7 %
Germany
5 %
Other
7 %
Currency exposure
USD
48 %
EUR
18 %
DKK
13 %
SEK
11 %
CHF
9 %
GBP
1 %
Documents

FUND INFORMATION
KID
PAI Statements
Fund rules
Prospectus
REPORTS
Monthly report
Annual report
Semi-annual report
SUSTAINABILITY DOCUMENTS
ESG Report
Shared sustainability documents
Sustainability-related disclosures

This is marketing communication. The past performance of the investment fund does not provide any guarantee of future results. Read the fund prospectus and KID (Key Information Document) before making any investment decisions. The fund prospectus and KID are available on English, Finnish and Swedish at our website.

Our funds
Latest news
Nordic Small Caps: New ideas and key takeaways from Carnegie’s Seminar

We had the opportunity to participate in Carnegie’s Nordic small-cap seminar in Stockholm. Over three days, we met with approximately 20 existing ... Read more

Is it time for active Equity Funds again? 

Trump’s tariff threats have been unsettling the markets for a couple of months. However, the country-specific tariffs announced last week exceeded even the ... Read more

This page was last updated

Web design: Wikström Media
Fondita online Fondita
online